<DOC>
	<DOCNO>NCT01811355</DOCNO>
	<brief_summary>The purpose study determine mexiletine effective treatment muscle cramp Amyotrophic Lateral Sclerosis ( ALS ) .</brief_summary>
	<brief_title>Mexiletine Treatment Muscle Cramps ALS</brief_title>
	<detailed_description>Background : Many ALS patient suffer painful muscle cramp , unfortunately medication proven help muscle cramp ALS . Reducing pain cause cramp - debilitate - could help people live ALS . Muscle cramp sudden , painful , involuntary contraction muscle . They cause nerve dysfunction . When examine nerve muscle electrically , see cramps burst high-frequency ( to150 Hz ) fire motor nerve cell . Cramps ALS believe result increase persistent sodium current sick low motor nerve cell . A medication call Quinine many year commonly use drug control cramp ALS , FDA advise use cramp potential risk ( e.g. , death ) . Today agreement treat cramp ALS . The American Academy Neurology recently encourage study treatment muscle cramp suggest lidocaine one drug special interest . Mexiletine : Mexiletine medication closely related lidocaine take mouth ( instead inject ) . Mexiletine stop type sodium current think cause muscle cramp . Mexiletine relatively old medication extensively study human . It show reduce electrical measure muscle cramp disease condition . For example , patient another severe nerve disease - Machado-Joseph disease ( SCA3 ) - mexiletine treatment lead decrease average number muscle cramp 24 3 cramp per month.. The safety profile mexiletine good , frequent side effect nausea abdominal symptom . These side effect rare dos ( 300 mg/day ) use study . In patient normal heart function , mexiletine minimal effect heart rhythm . In previous clinical trial , subject develop serious heart rate problem . Experimental Plan : Using multiple site within State California quickly enroll small number ( N=30 ) ALS patient severe muscle cramp . The study double-blinded , placebo control ( i.e. , investigator participant know pill contain mexiletine placebo ) , crossover ( subject receive two week mexiletine two week placebo ) study . After one week run , participant evaluate ability fill cramp diary . Participants fill diary randomly assign either mexiletine placebo first two week . For first three day 2-week period , one 150mg capsule take bed time . For day 4 14 one capsule twice per day take . Each treatment period 2 week intervene 1 week washout period - total study length 6 week . Safety monitor liver function study EKG 's .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Muscle Cramp</mesh_term>
	<mesh_term>Spasm</mesh_term>
	<mesh_term>Mexiletine</mesh_term>
	<criteria>ALS diagnose accord El Escorial criterion ( Awaji version ) : Possible , Probable , Definite . Experiencing cramps moderate severe symptom define willingness take medication symptom ≥2 cramp per week run week Life expectancy &gt; 6 month , estimate clinician Able take drug capsule mouth No significant EKG abnormality screen aspartate aminotransferase / alanine aminotransferase &lt; 2x upper limit normal measure screen Having successfully fill cramp diary cramp fasciculation scale six last seven day run period Inability communicate telephone email Allergy/ know sensitivity mexiletine Prior use mexiletine AV block unless subject pacemaker Cardiac arrhythmia Prior myocardial infarction Other significant EKG abnormality Liver disease History leucopenia ( WBC &lt; 3,500/mm3 ) Epilepsy Other serious unstable medical condition Pregnant woman Breastfeeding woman Active drug alcohol use dependence , opinion site investigator , would interfere adherence study requirement Use quinidine ( alone component Nuedexta® ) study Inability unwillingness subject give write informed consent Woman childbearing potential , willing use least two approve method contraception Use prohibit medication study</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Muscle cramp</keyword>
	<keyword>Cramp</keyword>
	<keyword>ALS</keyword>
	<keyword>Amyotrophic Lateral Sclerosis</keyword>
	<keyword>Lou Gehrig 's disease</keyword>
	<keyword>Motor Neuron Disease</keyword>
	<keyword>MND</keyword>
</DOC>